AnPac Bio-Medical Science Co. Ltd. (NASDAQ: ANPC) Receives College of American Pathologists Accreditation for U.S. Laboratory
AnPac Bio’s clinical laboratories are located in the U.S. and China, with a total of 142 patents issued as of March 2021 Cancer Differentiation Analysis (“CDA”) technology is AnPac Bio’s approach to early cancer detection and screening technology, with over 200,000 samples and cases to serve as a way of approaching cancer screening Company’s ownership percentage in subsidiary AnPai (Shanghai) Healthcare Management Consultant Co. Ltd. has increased from 20% to 60%, following rigorous regulatory assessments and audits With a focus on early cancer screening and detection, biotechnology company AnPac Bio-Medical Science (NASDAQ: ANPC) recently announced that its U.S. laboratory has…